
Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug (ACU193)-**Amyloid Beta Oligomer Complexes in Human CSF**

Erika N. Cline,¹ Elizabeth Johnson,¹ Oladayo Oladiran,² Jennifer Gillies,² Derrick Johnson,³ Nathan McOwen,³ Caitlin Hansen,² Jacob Wohlstadter,² Hao Zhang,¹ Eric Siemers,¹ Hugo Vanderstichele,^{1,4} Robert A. Dean,^{1,5} Jasna Jerecic¹ ¹Acumen Pharmaceuticals, Inc. (USA), ²Meso Scale Diagnostics, LLC. (USA), ³B2S Life Sciences (USA), ⁴Biomarkable (Belgium), ⁵Department of Pathology & Laboratory Medicine, Indiana University School of Medicine (USA)



Results

Figure 1. Sabirnetug (ACU193) is highly selective for soluble, synaptotoxic amyloid β oligomers (ABOs). In human neuronal membranes, AB monomers are cleaved from the amyloid precursor protein. Due to high hydrophobicity, Aβ monomers readily aggregate to oligomers (including protofibrils) or to larger insoluble amyloid fibrils, the primary component of amyloid plaques. The solubility of ABOs enables them to diffuse in the cellular milieu and bind to neuronal synapses. Their synaptic toxicity elicits downstream effects such as tau hyperphosphorylation, calcium dysregulation, and inhibition of long-term potentiation, ultimately resulting in the neuronal degeneration and cognitive impairment associated with Alzheimer's disease (AD).¹ Sabirnetug is > 500-fold selective for AβOs over Aβ monomers² and > 85-fold selective for A β Os over A β fibrils.³

GOAL: Aβ-targeting immunotherapies have traditionally used plaque reduction (assessed by PET) as a measure of target engagement. Because sabirnetug selectively targets ABOs, we aimed to develop a novel target engagement assay to measure the sabirnetug-A_βO complex in CSF.

(1) Cline et al., 2018, J Alzheimers Dis, 61(s1): S567-S610. (2) Krafft et al., 2022, Front Neurosci, 16: 848215. (3) Data on file

Target Engagement assay format on MSD S-Plex (Turbo) Immunoassay Platform

A β O selective detection (anti-A β O mAb) **C** Conly drug/A β O complex is measurable

> sabirnetug specific capture (anti-sabirnetug idiotypic mAb)

Figure 3. The target engagement assay for sabirnetug was designed to measure the sabirnetug-AβO complex in CSF. The assay was designed on the ultrasensitive MSD S-PLEX (aka Turbo) immunoassay platform. The sabirnetug specificity of the anti-idiotypic (anti-ID) capture antibody and the ABO-selectivity of the detection antibody yielded an assay highly specific and for the sabirnetug-ABO complex in CSF. A schematic presentation of the assay format is shown to the left.

Antibody pair chosen for optimal detection of endogenous CSF ABOs





Figure 4. Assay comparison of sabirnetug complexed with synthetic ABOs or CSF ABOs highlights importance of including biological samples in assay development. The detection antibody had a significant impact on detection of synthetic AβOs (ADDLs > 50 kDa used here)⁴ or CSF ABOs (sabirnetug spiked into human CSF) that appears to be most impacted by ABO selectivity rather than linear epitope of the antibody, suggesting conformational epitopes of the ACU-series antibodies (data not shown). n = 5 CSF samples. The CSF was a kind gift from Kaj Blennow (University of Gothenburg). S/N = signal/noise; mAb = monoclonal antibody. (4) Savage et al., 2014, *J Neurosci*, 34(8): 2884-2897



<u>Assay is specific for sabirnetug complexed with ABOs over AB monomers</u>




Figure 5. ACU988 was chosen as detection antibody to maximize detection of endogenous AβOs (Figure 4). Assay response to sabirnetug pre-incubated with oligometric A β (1-42) or monometric A β (1-40) was assessed at multiple concentrations (above) showing a 18-58x higher response for ABOs vs. monomer at matching concentrations and a 193x difference in the lower limit of detection (defined at S/N = 2). Note the interpretation of this data is complicated by the fact that $A\beta(1-40)$ does form ACU988immunoreactive oligomers in the time frame of the experiment (data not shown). By itself, sabirnetug has been shown to be > 500x selective for ABOs over monomer using experimental setups prohibiting monomeric aggregation.² S/N = signal/noise.





Figure 6. Assay achieves sufficient sensitivity to measure target engagement in INTERCEPT-AD CSF with reproducibility at < 20 % CV. Sensitivity, (left) The amount of sabirnetug-AβO complex in INTERCEPT-AD CSF was semi-quantitated against a calibrator of 900 pM sabirnetug (constant) and 10,000-2.44 pM ABOs (stabilized AB1-42 oligomers purchased from GBS Leiden); 1 AU/mL = 900 pM sabirnetug + 1 pM A β Os; AU = arbitrary units. 4PL non-linear regression was applied to the data (black), achieving a lower limit of detection (LLOD) of 2.31 AU/mL. Observed values in INTERCEPT-AD CSF samples plotted in red. Reproducibility, (right) % coefficient of variation (CV) of samples and controls (i.e., sabirnetug-AβO complexes in CSF) prepared at high, medium, low concentrations. P10, p90 = 10th & 90th percentile, respectively. INTERCEPT-AD samples run in duplicates.

RESEARCH HIGHLIGHTS

- \succ A novel immunoassay was developed for the A β O-selective antibody sabirnetug, measuring sabirnetug-A β O complexes in CSF
- \succ Comparison of assay performance with synthetic ABOs vs. CSF ABOs during assay development enabled optimization of the assay for detection of CSF ABOs
- \succ The resulting assay proved specific for ABOs bound to sabirnetug with sufficient sensitivity to measure target engagement in the CSF of INTERCEPT-AD participants receiving a single dose
- of 10 mg/kg sabirnetug or more, indicating clearance of the sabirnetug-ABO complex from the brain

> Target engagement across INTERCEPT-AD cohorts was dose-dependent and approached saturation at the highest doses administered, which proved useful in dose selection for Ph 2/3 trial of sabirnetug in AD (presented by Mirjam Trame at CTAD, October 2023 in Boston, MA, USA).

Figure 7. Application of assay to INTERCEPT-AD CSF shows dose-dependent target engagement at \geq 10 mg/kg, approaching saturation at 25 mg/kg Q2W. The assay had sufficient sensitivity to measure the sabirnetug-ABO complex in all dose groups except for 2 mg/kg SAD (single ascending dose). An Emax model was applied to the data showing saturation at 22.71 AU/mL sabirnetug-ABO complex and half maximal response (EC50) at 136 ng/mL sabirnetug in CSF (data from a pharmokinetic assay). Results from this target engagement Emax model were presented by Erika Cline in a virtual poster at CTAD, October 2023.



SCAN ME